Pandemic preparedness and response: Sustaining established coordination mechanisms for European adaptive platform trials and/or for cohort networks
Programme Category
Programme Name
Programme Description
Horizon Europe is the European Union (EU) funding programme for the period 2021 – 2027, which targets the sectors of research and innovation. The programme’s budget is around € 95.5 billion, of which € 5.4 billion is from NextGenerationEU to stimulate recovery and strengthen the EU’s resilience in the future, and € 4.5 billion is additional aid.
Identifier Code
Call
Summary
This topic aims at maintaining and strengthening existing strategic coordination mechanisms across adaptive platform trials and across cohort studies in Europe and beyond for avoiding redundancies, promoting complementarities and facilitating cooperation among EU-funded clinical research for infectious diseases. Proposals should strengthen the leading role of the EU in clinical research preparedness for future epidemics and pandemics, through ensuring coordination of the European adaptive platform trials and of the European cohort studies. The coordination mechanisms support the longer-term perspective of preparedness for future infectious disease epidemics and pandemics, where the networks enable the conduct of perpetual platform trials and of perpetual strategic cohorts with the in-built agility to pivot to emerging diseases when an epidemic strikes.
Detailed Call Description
Proposals should address the following areas:
- Fostering a trusted and proactive environment within the coordination mechanism that supports the timely exchange of research results, allows for discussion on challenges encountered in their research and finding solutions together to ensure cooperation and synergy within each network;
- Developing a common approach for the European clinical research to enable pragmatic solutions to shared challenges across European clinical trials and/or cohorts for pandemic preparedness and response, guaranteeing the best interest of European trial or study patients or volunteers;
- Promoting an optimal use of resources, based on a sound scientific approach and maximising the value added for the generation of scientific evidence, through a common baseline approach towards protocol development, harmonised and FAIR data collection and analysis leveraging existing initiatives;
- Involving relevant European stakeholders, such as representatives from regulatory authorities, industry, policymakers, patient organisations, etc., as well as relevant non-European networks and stakeholders;
- Promoting the visibility and attractiveness of European adaptive platform trials and/or cohorts for clinical investigators in Europe and beyond ; as well as active communication with the science community, patient advocacy groups and other stakeholders, to develop trust, and also promote innovative approaches;
- Partners within the coordination mechanism should develop a plan to ensure its sustainability. Coordination with the European Pandemic Preparedness Partnership and the European Health Preparedness and Emergency Response Authority (HERA) is expected.
The coordination mechanism supports reflections e.g. on the diversity of the trial target populations (e.g. primary care or hospitalised patients) or on different possible medical countermeasures (e.g. therapeutics, vaccines), etc. Within the cohort network, the coordination mechanism supports reflections e.g. on diversity in type of cohorts and research questions to be addressed, or on harmonised approaches to data collection and analysis, etc.
Call Total Budget
Financing percentage by EU or other bodies / Level of Subsidy or Loan
100%
Contribution per project: between €1,00 and €2,00 million
Thematic Categories
- Health
- Research, Technological Development and Innovation
Eligibility for Participation
- International Organisations
- Legal Entities
- Researchers/Research Centers/Institutions
Eligibility For Participation Notes
In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, legal entities established in the United States of America may exceptionally participate as a beneficiary or affiliated entity, and are eligible to receive Union funding.
Coordinators of projects must be legal entities established in an EU Member State or Associated Country.
Proposals should address proper connections with relevant European initiatives and organisations, such as the European Pandemic Preparedness Partnership, the European Health Preparedness and Emergency Response Authority (HERA), as well as the European Medicines Agency (EMA) and the European Centre for Disease Prevention and Control (ECDC).
Proposals should also be open to engage with global initiatives such as the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R), the Global Health EDCTP3 Joint Undertaking, or the World Health Organization (WHO).
Call Opening Date
Call Closing Date
National Contact Point(s)
Research and Innovation Foundation
29a Andrea Michalakopoulou, 1075 Nicosia
P.O.Box 23422, 1683 Nicosia
Telephone: +357 22205000
Email Address: support@research.org.cy
Website: https://www.research.org.cy/en/
Contact Persons:
George Christou
Scientific Officer
Email: gchristou@research.org.cy
Ioannis Theodorou
Scientific Officer
Telephone: +357 22 205 038
Contact Email: itheodorou@research.org.cy
(Publish Date: 09/02/2023-for internal use only)
EU Contact Point
European Commission, Directorate-General for Research and Innovation
https://ec.europa.eu/info/departments/research-and-innovation_en#contact